Unknown

Dataset Information

Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.


ABSTRACT: Hemophilia B is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), with an incidence of approximately once every 30,000 male births in all populations and ethnic groups. When severe, the disease leads to spontaneous life threatening bleeding episodes. When untreated, most patients die from bleeding complications before 25 years of age. Current therapy requires frequent intravenous infusions of therapeutic recombinant or plasma-derived protein concentrates containing FIX. Most patients administer the infusions at home every few days, and must limit their physical activities to avoid abnormal bleeding when the FIX activity levels are below normal. After completing the pivotal Phase III clinical trial, a new therapeutic FIX preparation that has

SUBMITTER: Miguelino MG 

PROVIDER: S-EPMC4133029 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature